Bibliography
About the MPP, Medicines Patent Pool, http://www.medicinespatentpool.org/about
About PMPRB, Patented Medicine Prices Review Board, http://pmprb-cepmb.gc.ca/home
‘Domestic Legislation and Court Decisions on Intellectual Property and Public Health in South Africa’, http://www.localpharmaproduction.net/fileadmin/dateien/Country_studies/Country_analysis_-_South_Africa.pdf [accessed 12 December 2013].
‘Draft National Policy on Intellectual Property 2013’ (South Africa), http://ipasa.co.za/wp-content/uploads/2013/07/IPASA-Extracts-from-Submission-made-on-the-DRAFT-NATIONAL-POLICY-ON-IP....pdf
Global Communication on HIV and the Law, Regional Issues Brief: Intellectual Property Rights and Access to Medicines’ (17 February 2011), http://www.hivlawcommission.org/resources/aprd/IssuesBrief_IPR.pdf
Human Development Index (HDI), Human Development Reports, UNDP, http://hdr.undp.org/en/statistics/hdi
Abbott, F., ‘The Doha Declaration on the TRIPS Agreement and Public Health: Lighting a Dark Corner at the WTO’, Journal of International Economic Law, 5 (2002), 469–505, http://dx.doi.org/10.1093/jiel/5.2.469
―, ‘Seizure of Generic Pharmaceuticals in Transit Based on Allegations of Patent Infringement: A Threat to International Trade, Development and Public Welfare’, WIPO Journal, 1 (2009), 43–50, http://dx.doi.org/10.
4337/9781849804929.00012
Abbot, Ryan, ‘Potential Elements of the WHO Global R&D Treaty: Tailoring Solutions for Disparate Contexts’, Intellectual Property Watch (29 January 2013), http://www.ip-watch.org/2013/01/29/potential-elements-of-the-who-global-rd-treaty-tailoring-solutions-for-disparate-contexts
Abhiyan, Jan Swasthya, National Coordination Committee, ‘Access to Essential Medicines’ 37 (February 2007), http://www.healthpolicy.cn/rdfx/jbywzd/gjjy2/yd/yjwx/201002/P020100227572014659949.pdf
Abramowicz, Michael, ‘Perfecting Patent Prizes,’ Vanderbilt Law Review, 56 (2003), 115–21, http://dx.doi.org/10.2139/ssrn.292079
Addor, Felix, ‘Switzerland’s Proposal for Disclosure of the Source of Genetic Resources and Traditional Knowledge in Patent Applications’, in Disclosure Requirements: Ensuring Mutual Supportiveness between the WTO TRIPS Agreement and the CBD, ed. by Martha Chouchena-Rojas, Manuel Ruiz Muller, David Vivas, and Sebastian Winkler (Geneva: International Centre for Trade and Sustainable Development, 2005), pp. 35–40.
Afrin, Rafia, and Daniel Sabet, ‘Will Bangladesh’s New Competition Law Prove Effective?’ (1 July 2012), http://ces.ulab.edu.bd/wp-content/uploads/sites/18/2015/07/Competition_law_07-12.pdf
Agutu, Omolo Joseph, ‘Least Developed Countries and the TRIPS Agreement: Arguments for a Shift to Voluntary Compliance’, African Journal of International and Comparative Law, 20.3 (2012), 423–47, http://dx.doi.org/10.3366/ajicl.2012.0044
Agarwala, Aditi, and Akhil Prasad, ‘Patent versus Patients: Reflections on Blatant Patent Regime’, International Journal of Liability and Scientific Enquiry, 2.2 (2009), 147–61, http://dx.doi.org/10.1504/ijlse.2009.023984
Ahmad, A.K. Monaw-war Uddin, Competition, Regulation and the Role of the State: The Case of Bangladesh (10 July 2011).
Ahammad, H., ‘Foreign Exchange and Trade Policy Issues in a Developing Country: The Case of Bangladesh’ (Working Paper No. 95/1, Canberra Research School of Pacific and Asian Studies, Australian National University, 1995).
Amran, Md Shah, TRIPS, ‘Impacts of TRIPS on local Pharma sector’ (27 January 2005), http://www.pharmabiz.com/article/detnews.asp?articleid=25958§ionid=50
Anand, Grover, ‘Anti-competitive Practices in Patent Licensing Arrangements and the Scope of Competition Law/Policy in Dealing with Them’ (AMTC, National Workshop on Patent and Public Health, Ministry of Health, India, 11 April 2005).
Anderson, R.D., and H. Wager, ‘Human Rights, Development and the WTO: The Cases of Intellectual Property and Competition Policy’, Journal of International Economic Law, 9.3 (2006), 707–47, http://dx.doi.org/10.1093/jiel/jgl022
Anwar, Syed Farhat, ‘Pharmaceutical Sector of Bangladesh: Trade Prospects with Nepal and the Impact of TRIPS’, in Towards Greater Sub Regional Economic Cooperation: Limitation, Obstacles and Benefits, ed. by Forrest E. Cookson and A.K.M. Shamsul Alam (Dhaka: University Press Limited, 2002), pp. 217–58.
Armstrong, Chris, Jeremy de Beer, Dick Kawooya, Achal Prabhala, and Tobias Schonwetter, Copyright and Access to Knowledge in Eight African Countries (Claremont: UCT Press, 2010).
Arthurs, H.W., Law and Learning: Report to the Social Sciences and Humanities Research Council of Canada by the Consultative Group on Research and Education in Law (Ottawa: Social Sciences and Humanities Research Council of Canada, 1983).
Arundel, A., and G. van de Paal, Innovation Strategies of Europe’s Largest Industrial Firms (unpublished manuscript, Maastricht Economic and Social Research and Training Centre, 1995).
Arvind, S., ‘Putting Some Numbers on the TRIPS Pharmaceutical Debate’, International Journal of Technology Management, 10 (1995), 252–68.
Ayres, Ian, and John Braithwaite, Responsive Regulation: Transcending the Deregulation Debate (Oxford: Oxford University Press, 1992).
Avafia, Tenu, Jonathan Berger, and Trudy Hartzenberg, ‘The Ability of Select Sub-Saharan Africa Countries to Utilize TRIPS Flexibilities and Competition Law to Ensure a Sustainable Supply of Essential Medicines: A Study of Producing and Importing Countries’ (tralac Working Paper No. 12/2006, August 2006), http://www.section27.org.za/wp-content/uploads/2010/10/Avafia-Berger-and-Hartzenberg.pdf
Azam, Mohammad Monirul, and Morshed Mahmud Khan, ‘TRIPS Agreement and Protection of National Interest: Contention between Developed and Developing Countries’, The Chittagong University Journal of Law, 5 (2000), 1–34.
―, ‘Establishment of the WTO and Impacts on the Legal System of Bangladesh’, Macquarie Journal of Business Law, 3 (2006), 23–45.
―, Effectiveness of the Intellectual Property Enforcement Mechanisms under the TRIPS Agreement: The Context of Bangladesh (Geneva: World Intellectual Property Organization Academy—Turin Research Paper Series, 2007), 102–57.
―, Intellectual Property, WTO and Bangladesh (Dhaka: New Warsi Book Co., 2008).
―, ‘Revisiting the Climate Change Negotiation under the UNFCCC: In Search of Effective Framework for Negotiation and Technology Transfer’ (2009), http://www.conference.unitar.org/yale/sites/conference.unitar.org.yale/files/Paper_Azam.pdf
―, ‘Journey towards WTO Legal System and the Experience of Bangladesh: The Context of Intellectual Property’ (The Society of International Economic Law 2010 Conference, International Economic Law and Policy [IELPO], University of Barcelona, 2010).
―, and Kristy Richardson, ‘Access to Medicines and Pharmaceutical Patent Protection under the TRIPS Agreement: A Review of Literature on the Challenges for Least Developed Countries,’ Intellectual Property Forum Journal, 84 (2011), 59–67.
―, ‘Climate Change Resilience and Technology Transfer: The Role of Intellectual Property’, Nordic Journal of International Law, 80.4 (2011), 485–505, http://dx.doi.org/10.1163/157181011x598445
―, ‘Globalising Standard of Patent Protection in WTO Law and Policy Options for the LDCs’, Chicago-Kent Journal of Intellectual Property, 13.2 (2014), 402–88.
―, ‘The Experiences of Patent Law Reforms in Brazil, India and South Africa and Lessons for Bangladesh, Akron Intellectual Property Journal, 7.2 (2014), 61–100.
―, and Kristy Richardson, ‘Pharmaceutical Patent Protection and TRIPS Challenges for Bangladesh: An Appraisal of Bangladesh’s Patent Office and Department of Drug Administration’, Bond Law Review, 22.2 (2010a), 1–15.
―, and Kristy Richardson, ‘TRIPS Compliant Patent Law and the Pharmaceutical Industry in Bangladesh: Challenges and Opportunities’, LAWASIA Journal (2010b), 141–54.
―, and Yacouba Sabere Mounkoro, ‘Intellectual Property Protection for the Pharmaceuticals: An Economic and Legal Impacts Study with Special Reference to Bangladesh and Mali’, Le Griot Du Développement, § 7.1.2 (June 1, 2012), http://legriotdudeveloppement.blogspot.co.uk/2012/06/intellectual-property-protection-for.html
―, and Mahesti Okitasari, ‘Environmental Governance and National Preparedness towards 2030 Agenda for Sustainable Development: A Tale of Two Countries’, Global Environmental Research 19.2 (2015), 217–25.
Baker, Dean, and Noriko Chatani, ‘Promoting Good Ideas on Drugs: Are Patents the Best Way? The Relative Efficiency of Patent and Public Support for Bio-Medical Research’ (briefing Paper, 2002), http://cepr.net/publications/reports/promoting-good-ideas-on-drugs-are-patents-the-best-way
Balat, Mohamed Abu El Farag, and Mohamad Hossam Loutfi, ‘The TRIPS Agreement and Developing Countries: A Legal Analysis of the Impacts of the New IPR’s Law on the Pharmaceutical Industry in Egypt’, 2 Web JCILI (2004).
Banta, D.H., ‘Worldwide Interest in Global Access to Drugs’, The Journal of the American Medical Association, 285.22 (2001), 2844–46, http://dx.doi.org/10.1001/jama.285.22.2844
Barai, Munim Kumar, ‘Economic Liberalization and Macro Economic Stability in Bangladesh: An Overview’ (Paper presented at the National Workshop of the Bangladesh Institute of International and Strategic Studies [BIISS], Dhaka, 29 February to 1 March 2000).
Barbosa, D.B., M. Chon, and A.M. von Hase, ‘Slouching Towards Development in International Intellectual Property’, Michigan State Law Review, 1 (2007), 114–23.
Barnes, Stephen, ‘Note: Pharmaceutical Patents and TRIPS: A Comparison of India and South Africa’, Kentucky Law Journal, 91 (2003), 911–34.
Basheer, Shamnad, and Mrinalini Kochupillai, ‘TRIPS, Patents and Parallel Imports: A Proposal for Amendment’, Indian Journal of Intellectual Property Law, 2 (2009), 63–86.
―, ‘Indian Government Committee Says “No” to Data Exclusivity’ (6 June 2007), http://spicyip.com/2007/06/indian-government-committee-says-no-to.html
―, ‘India’s Tryst with TRIPS: The Patents (Amendment) Act, 2005’, Indian Journal of Law and Technology, 1 (2005), 15–30.
Bass, Naomi A., ‘Implications of the TRIPS Agreement for Developing Countries: Pharmaceutical Patent Laws in Brazil and South Africa in the 21st Century’, George Washington International Law Review 34 (2002), 191–222.
Basso, Maristela, ‘Intervention of Health Authorities in Patent Examination: The Brazilian Approach of the Prior Consent’, International Journal of Intellectual Property Management, 1 (2006), 54–74, http://dx.doi.org/10.1504/ijipm.2006.011022
Bermudez, Jorge A. Z., and Oliveira, Maria Auxiliadora (eds.) Intellectual Property in the Context of the WTO TRIPS Agreement: Challenges for Public Health (Rio de Janeiro: Centre for Pharmaceutical Policies and WHO, 2004).
Bhatt, Shiv Raj, ‘Nepal: Public Health under WTO’, South Asian Journal, 11 (2006), 29–40.
Bhattacharya, Debapriya, and Lisa Borgatti, ‘An Atypical Approach to Graduation from LDC Category: The Case of Bangladesh’, South Asia Economic Journal, 13.1 (2012), 1–25, http://dx.doi.org/10.1177/139156141101300101
Biadgleng, Ermias, and Viviana Tellez, The Changing Structure and Governance of Intellectual Property Enforcement’ (South Centre Research Paper No. 15, January 2008), http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1210622
Blakeney, Michael, Trade Related Aspects of Intellectual Property Rights: A Concise Guide to the TRIPS Agreement (London: Sweet & Maxwell, 1996).
Blake, R., ‘Integrating Quantitative and Qualitative Methods in Family Research’, Families Systems and Health, 7.4 (1989), 411–27, http://dx.doi.org/10.1037/h0089788
Blanche, Martin Terre, and Kevin Durrheim, Research in Practice: Applied Methods for the Social Sciences (Cape Town: University of Cape Town Press, 1999).
Blismas, Nick G., and Andrew R.J. Dainty, ‘Computer-aided Qualitative Data Analysis: Panacea or Paradox?’, Building Research and Information, 31.6 (2003), 455–63, http://dx.doi.org/10.1080/0961321031000108816
Board of Investment, Bangladesh, Market Overview: Bangladesh is Poised for Major Growth in its Pharmaceutical Industry, http://www.boi.gov.bd/site/page/7b31d826-368c-4ed9-8077-d16310433060/Life-Science
Boldrin, Michele, and David K. Levine, Against Intellectual Monopoly (Cambridge: Cambridge University Press, 2008), http://dx.doi.org/10.1017/cbo9780511510854
Bond, Patrick, ‘Globalization, Pharmaceutical Pricing, and South African Health Policy: Managing Confrontation with U.S. Firms and Politicians’, International Journal of Health Services, 29 (1999), 765–92, http://dx.doi.org/10.2190/4ma6-53e3-le1x-c1yy
Boonfueng, Krithpaka, ‘Parallel Imports in Pharmaceuticals: Increase Access to HIV Drugs’, Thailand Law Forum (2010), http://www.thailawforum.com/articles/hivdrugs1.html
Braithwaite, John and Ian Ayres, Responsive Regulation: Transcending the Deregulation Debate (Oxford: Oxford University Press, 1992).
Branstetter, Lee G., R. Fisman, and C.F. Foley, ‘Do Stronger Intellectual Property Rights Increase International Technology Transfer? Empirical Evidence from U.S. Firm-level Panel Data’ (Working Paper No. 3305, World Bank Policy Research, 2004).
Brant, Jennifer and Malpani, Rohit, ‘Eye on the Ball Medicine Regulation—Not IP Enforcement—Can Best Deliver Quality Medicines’ (2 February 2011), http://www.oxfam.org/sites/www.oxfam.org/files/eye-on-the-ball-medicine-regulation-020211-en.pdf
Brezis, Mayer, ‘Big Pharma and Health Care: Unsolvable Conflict of Interests Between Private Enterprise and Public Health’, Israel Journal of Psychiatry and Related Sciences, 45 (2008), 83–94.
Bronckers, Marco C.E.J., ‘The Exhaustion of Patent Rights under World Trade Organization Law’, Journal of World Trade Law, 32.5 (1998), 137–59.
Browne, Dennis, ‘Dispute Settlement in the WTO: How Friendly Is It for the LDCs?’ (Paper No. 45, Centre for Policy Dialogue [CPD], January 2005).
Business Wire Pharmaceutical, ‘Research and Markets: Pharmaceutical Pricing and Reimbursement in Brazil: Population and Demand for Pharmaceuticals is Forecast to Increase in the Next 12 Years’ (Press Release, 5 January 2010), http://www.reuters.com/article/2010/01/25/idUS147453+25-Jan-2010+BW
20100125
Cahoy, Daniel R., ‘An Incrementalist Approach to Patent Reform Policy’, Journal of Legislation and Public Policy, 9 (2006), 589–618.
Calvani, Terry and Alderman, Karen, ‘BRIC in the International Merger Review Edifice’, Cornell International Law Journal, 43 (2010), 73–145.
Cameron, Edwin, and Jonathan Berger, ‘Patents and Public Health: Principle, Politics and Paradox’, SCRIPT-ed, 1.4 (2004), 517–44, http://www2.law.ed.ac.uk/ahrc/script-ed/docs/cameron.asp
Caracelli, V.J., and J.C. Greene, ‘Data Analysis Strategies for Mixed-method Evaluation Designs’, Educational Evaluation and Policy Analysis, 15.2 (1993), 195–207, http://dx.doi.org/10.3102/01623737015002195
Carlson, Steven C., ‘Note, Patent Pools and the Antitrust Dilemma’, Yale Journal on Regulation, 16 (1999), 352–59.
Cassier, Maurice, and Marilena Correa, ‘Intellectual Property and Public Health: Copying of HIV/AIDS Drugs by Brazilian Public and Private Pharmaceutical Laboratories,’ RECIIS Electronic Journal of Communication, Information and Innovation in Health, 1.1 (2007), 83–90, http://dx.doi.org/10.3395/reciis.v1i1.38en
Chandra, Rajshree, ‘The Role of National Laws in Reconciling Constitutional Right to Health with TRIPS Obligations: An Examination of the Glivec Patent Case in India’, in Incentives for Global Public Health—Patent Law and Access to Essential Medicines, ed. by Thomas Pogge, Mathew Rimmer, and Kim Rubenstein (Cambridge: Cambridge University Press, 2010), pp. 381–405, http://dx.doi.org/10.1017/cbo9780511750786.018
Charmaz, Kathy, ‘The Grounded Theory Method: An Explication and Interpretation’, in Contemporary Field Research: A Collection of Readings, ed. by Robert M. Emerson (Beverly Hills, CA: Sage Publications, 1983), pp. 109–26.
Chaudhary, Abhilash, ‘Compulsory Licensing of IPRS and Its Effect on Competition’, http://cci.gov.in/images/media/ResearchReports/Compulsory Licensing of IPRs and Its Effect on Competition.pdf [accessed 8 September 2014].
Chaudhuri, Sudip, ‘Indian Generic Companies, Affordability of Drugs and Local Production in Africa with Special Reference to Tanzania, IKD’ (Working Paper No. 37, September 2008), http://oro.open.ac.uk/26384/2/
Chaudhuri, Sudip, The Indian Pharmaceutical Industry—Post TRIPS (Indian Institute of Management, 2009).
Chen, S. Wu, S. Hang, J. and Shi, L., ‘Impact of Medical Data Protection on Drug Expenditure and Accessibility in China’, Chinese Journal of New Drugs, 21.20 (2012), 2353–5.
Choudhuri, Subham, Pinelopi K. Goldberg, and Panle Jia, ‘Estimating the Effects of Global Patent Protection in Pharmaceuticals: A Case Study of Quinolones in India’ (Yale University, 2004), http://www.nber.org/papers/w10159
Chowdhury, Samson H., ‘Progress in Pharmaceutical Industries in Bangladesh’, Korea Times (27 March 2009), http://www.koreatimes.co.kr/www/news/include/print.asp?newsIdx=21326
Chowdhury, Zafarullah, The Politics of Essential Drugs—The Makings of a Successful Health Strategy: Lessons from Bangladesh (London: Zed Books, 1995).
Cohen, W.M., R.R. Nelson, and J. Walsh, ‘Appropriability Conditions and Why Firms Patent and Why They Do Not in the U.S. Manufacturing Sector’ (Working Paper, Carnegie Mellon University, 1997).
Cohen, Dani and Jennifer Cohen, ‘Competition Commission Finds Pharmaceutical Firms in Contravention of the Competition Act’ (Competition Commission, 2003), http://www.cptech.org/ip/health/sa/cc10162003.html
Commission on Intellectual Property Rights (CIPRS), Integrating Intellectual Property Rights and Development—Final Report (2002).
Commonwealth Tertiary Education Commission, Report of the Working Party on Post-secondary Rural Education (AGPS, November 1987).
Conconi, Paola, and Carlo Perroni, ‘Self-enforcing International Agreements and Domestic Policy Credibility’ (Working Paper No. 114/03, CSGR, July 2003).
Converse, J.M., and S. Presser, Survey Questions: Handcrafting the Standardized Questionnaire (Beverley Hills, CA: Sage, 1986).
Cooper, Helene, Rachel Zimmerman, and Laurie Mcginley, ‘AIDS Epidemic Puts Drug Firms in a Vise: Treatment vs. Profits’, Wall Street Journal (March 2, 2001).
Correa, Carlos, ‘Integrating Public Health Concerns into Patent Legislations in Developing Countries’ (Geneva: South Centre, Chernin du Charnpd’ Anier 17, 1211, 2000), http://apps.who.int/medicinedocs/pdf/h2963e/h2963e.pdf
―, Intellectual Property Rights, The WTO and Developing Countries: The TRIPS Agreement and Policy Options (London: Zed Books, 2000).
―, Protection of Data Submitted for the Registration of Pharmaceuticals: Implementing the Standards of the Trips Agreement (Geneva: South Centre, 2002)
―, ‘The WTO Dispute Settlement Mechanism TRIPS Rulings and the Developing Countries’, The Journal of World Intellectual Property, 4 (2001), 239–54, http://dx.doi.org/10.1111/j.1747-1796.2001.tb00088.x
―, ‘Protecting Test Data for Pharmaceutical and Agrochemical Products under Free Trade Agreements, UNCTAD–ICTSD Dialogue on Moving the Pro-development IP Agenda Forward: Preserving Public Goods in Health, Education and Learning’ (United Nations Conference on Trade and Development, 29 November to 3 December 2004), http://www.iprsonline.org/unctadictsd/bellagio/docs/Correa_Bellagio4.pdf
―, ‘Guidelines for the Examination of Pharmaceutical Patents: Developing a Public Health Perspective: A Working Paper’ (WHO ICTSD UNCTAD (January, 2007) http://ictsd.net/downloads/2008/04/correa_pharmaceutical-patents-guidelines.pdf
―, ‘Intellectual Property in LDCs: Strategies for Enhancing Technology Transfer and Dissemination’, 3, 18 (UNCTAD The Least Developed Countries Report 2007, Background Paper No. 4, 2007), http://unctad.org/Sections/ldc_dir/docs/ldcr2007_Correa_en.pdf
―, ‘Intellectual Property and Competition Law: Exploration of Some Issues of Relevance to Developing Countries’ (Geneva: International Centre for Trade and Sustainable Development, 2007), http://www.iprsonline.org/resources/docs/corea_Oct07.pdf
―, ‘TRIPS and R&D Incentives in the Pharmaceutical Sector’ (Communication on Macroeconomics and Health, Working Paper No. WG2:11, November 2011), http://library.cphs.chula.ac.th/Ebooks/HealthCareFinancing/Working
Paper_WG2/WG2_11.pdf
―, and Yusuf Abdulqawi A. (eds.) Intellectual Property and international Trade: TRIPs Agreement (London: Kluwer Law International, 1998).
Cotterrell, Roger, ‘Why Must Legal Ideas Be Interpreted Sociologically?’, Journal of Law and Society, 25.2 (1998), 171–92, http://dx.doi.org/10.1111/1467-6478.00086
Cottier, Thomas, and Ingo Meitinger, ‘The TRIPS Agreement without a Competition Agreement’ (Paper presented at the Trade and Competition in the World Trade Organization and Beyond, Venice, 4–5 December 1998).
―, ‘From Progressive Liberalization to Progressive Regulation in WTO Law’, Journal of International Economic Law, 9.4 (2006), 779–821, http://dx.doi.org/10.1093/jiel/jgl029
―, ‘The Exhaustion of Intellectual Property Rights—A Fresh Look’, IIC International Review of Intellectual Property and Competition, 39 (2008), 755–57.
―, Lalani Shaheeza, and Michelangelo Temmerman, ‘Use It or Lose It? Assessing the Compatibility of the Paris Convention and TRIPS with Respect to Local Working Requirements’ (Working Paper, World Trade Institute, University of Bern, 18 February 2013), http://dx.doi.org/10.1093/jiel/jgu026
Cotula, Lorenzo, ‘Property Rights, Negotiating Power and Foreign Investment: An International and Comparative law Study on Africa’ (Unpublished doctoral thesis, University of Edinburgh School of Law, 2009).
Cownie, F., Legal Academics: Culture and Identities (Oxford and Portland, Oregon: Hart Publishing, 2004).
Cox, Krista L., ‘The Medicines Patent Pool: Promoting Access and Innovation for Life-saving Medicines through Voluntary Licenses,’ Hastings Science and Technology Law Journal, 4 (2012), 292–325.
Creswell, John W., and Vicki L. Plano Clark, Designing and Conducting Mixed Methods Research (London and Washington, DC: Sage Publications, 2007).
Creswell, John W., Research Design: Qualitative, Quantitative, and Mixed Methods Approaches (London and Washington, DC: Sage Publications, 2009).
Crosland, Maurice, and Antonio Galvez, ‘The Emergence of Research Grants Within the Prize System of the French Academy of Sciences’, Social Studies of Science, 19 (1989), 71–100, http://dx.doi.org/10.1177/030631289019001002
Cullet, Philippe, ‘Patent Bill, TRIPS and Right to Health’, Economic and Political Weekly, 36.43 (27 October 2001), http://www.ielrc.org/content/a0108.pdf
Danzon, Patricia and Michael Furakawa, ‘Prices and Availability of Pharmaceuticals’, Health Affairs, 27 (2008), 221–25, http://dx.doi.org/10.1377/hlthaff.27.1.221
Davis, Lee N., ‘Should We Consider Alternative Incentives for Basic Research? Patents vs. Prizes’ (Paper presented at the DRUID Summer Conference, 6–8 June 2002).
Dent, Chris, ‘An Exploration of the Principles, Precepts and Purposes that Provide Structure to the Patent System’, Intellectual Property Quarterly, 4 (2008), 456–77, http://dx.doi.org/10.2139/ssrn.1371925
Descombe, M., The Good Research Guide: For Small-scale Social Research Projects (Berkshire and New York: Open University Press, 1998).
Dorji, Tandi, ‘Effect of TRIPS on Pricing, Affordability and Access to Essential Medicines in Bhutan’, Journal of Bhutan Studies, 16 (2007), 128–41.
Drahos, Peter, ‘BITS and BIPS: Bilateralism in Intellectual Property’, Journal of World Intellectual Property, 4 (2001), 791–801, http://dx.doi.org/10.1111/j.1747-1796.2001.tb00138.x
―, and John Braithwaite, ‘Intellectual Property, Corporate Strategy, Globalisation: TRIPs in Context’, Wisconsin International Law Journal, 20.3 (2002), 451–80.
―, ‘Developing Countries and International Intellectual Property Standard Setting’ (Study Paper No. 8, CIPRS).
Dreyfuss, Rochelle Cooper, ‘The Role of India, China, Brazil and Other Emerging Economies in Establishing Access Norms and Intellectual Property and Intellectual Property Law Making’ (IICJ Working Paper, 2009), http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1442785
Driscoll, David L., Afua Appiah-Yeboah, Philip Salib, and Douglas J. Rupert, ‘Merging Qualitative and Quantitative Data in Mixed Methods Research: How To and Why Not’, Ecological and Environmental Anthropology, 3.1 (2007), 19–28.
Duke, Lynne, ‘Nkosazana Zuma—Activist Health Minister Draws Foes in S. Africa’, Washington Post (11 December 1998).
Dutfield, Graham, ‘Delivering Drugs to the Poor: Will the TRIPS Amendment Help?’, Journal of Law and Medicine, 34.2 (2008), 107–24.
Edwards, Monica, Luis M. Sánchez-Ruiz, and Enrique Ballester-Sarrias, ‘Analyzing the Obstacles for the Academic and Organizational Change in Universities’ (Paper presented at the International Conference on Engineering Education—ICEE 2007, Coimbra, 3–7 September 2007).
Elbeshbishi, Amal Nagah, ‘TRIPS and Public Health—What Should African Countries Do?’ (Work in Progress No. 49, African Trade Policy Centre, January 2007).
Ellis, Karen, Rohit Singh, Shaikh Eskander, and Iftekharul Huq, Assessing the Economic Impact of Competition: Findings from Bangladesh (ODI, 2010).
El-Said, Mohammed, ‘The Road from TRIPS-Minus, to TRIPS, to TRIPS-Plus Implications of IPRs for the Arab World’, The Journal of World Intellectual Property, 4 (2001), 53–79, http://dx.doi.org/10.1111/j.1747-1796.2005.tb00237.x
―, Public Health Related TRIPS-Plus Provisions in Bilateral Trade Agreements: A Policy Guide for Negotiators and Implementers in the Eastern Mediterranean Region (WHO and ICTSD, 2010).
Faiz, Kermani, ‘Brazil—Not a Market for Faint Hearted’ (Contract Pharma, October, 2005).
Farlow, Andrew, ‘A Global Medical Research and Development Treaty: An Answer to Global Health Needs?’ (IPN Working Paper on Intellectual Property, Innovation and Health, 2007), http://www.andrewfarlow.com/global_medical_research_treaty.pdf
Fasan, Olu, ‘Commitment and Compliance in International Law: A Study of the Implementation of the WTO TRIPS Agreement in Nigeria and South Africa’, African Journal of International and Comparative Law, 20.2 (2012), 191–228, http://dx.doi.org/10.3366/ajicl.2012.0031
Ferranti, David de, ‘Can Patent Pools Get More AIDS Drugs to Patients?’, Huffington Post (9 April 2012), http://www.huffingtonpost.com/david-de-ferranti/aids-drugs_b_1404218.html
Ferreira, L., ‘Access to Affordable HIV/AIDS Drugs: The Human Rights Obligations of Multinational Pharmaceutical Corporations’, Fordham Law Review, 71.3 (2002), 1133–79.
Fink, C., ‘How Stronger Patent Protection in India Might Affect the Behavior of Transnational Pharmaceutical Industries’ (Working Paper No. 2352, World Bank, 2000), http://elibrary.worldbank.org/doi/abs/10.1596/1813-9450-2352
Finston, Susan, ‘India: A Cautionary Tale on the Critical Importance of Intellectual Property Protection’, Fordham Intellectual Property, Media and Entertainment Law Journal, 12 (2002), 887–95.
Fisher, William W., and Talha Syed, ‘A Prize System as a Partial Solution to the Health Crisis in the Developing World’ (Discussion Paper No. 5, Petrie-Flom Center for Health Law Policy, Biotechnology and Bioethics at Harvard Law School, 2009), https://www.law.berkeley.edu/files/Fisher_Prizes12.pdf
―, and Cyrill P. Rigamonti, ‘The South Africa AIDS Controversy: A Case Study in Patent Law and Policy, Harvard Law School’ (10 February 2005), http://cyber.law.harvard.edu/people/tfisher/South Africa.pdf
Flynn, Mathew, ‘Corporate Power and State Resistance: Brazil’s Use of TRIPS Flexibilities for Its National AIDS Program’, in Intellectual Property, Pharmaceuticals and Public Health, ed. by Kenneth C. Shadlen, Samira Guennif, Alenka Guzman, and N. Lalitha (Cheltenham: Edward Elgar, 2011), pp. 149–77, http://dx.doi.org/10.4337/9780857938619.00011
Ford, Matthew W., and Bertie M. Greer, ‘Profiling Change: An Empirical Study of Change Process Patterns’, Journal of Applied Behavioural Science, 42.4 (2006), 445–67, http://dx.doi.org/10.1177/0021886306293437
Fukuda-Parr, Sakiko, ‘The Human Development Paradigm: Operationalizing Sen’s Ideas on Capabilities’, Feminist Economics, 9 (2003), 301–03, http://dx.doi.org/10.1080/1354570022000077980
Gao, Yafei, The Conflict and Coordination between Biological Pharmacy’s Intellectual Property Protection and Public Health (Peking: Peking University Press, October 2011).
Garrison, Christopher, ‘Exception to Patent Rights in Developing Countries’ (Issue Paper No. 17, UNCTAD–ICTSD Project on IPR and Sustainable Development, 2006), http://www.unctad.org/en/docs/iteipc200612_en.pdf
GATT, Negotiating Group on TRIPs, ‘Including Trade in Counterfeit Goods’, Meeting of Negotiating Group of 11–13 September 1989, GATT Doc. MTN.GNG/NG11/15, p. 20 (26 October 1989), https://www.wto.org/gatt_docs/English/SULPDF/92080131.pdf
Gerhardsen, Tove Iren S., ‘Developing Countries Propose TRIPS Amendment on Disclosure’, Intellectual Property Watch (1 June 2006, 1344), http://www.ip-watch.org/2006/06/01/developing-countries-propose-trips-amendment-on-disclosure
Ghosh, Goutam, ‘Patent Pool: A Technology Management Option for Developing New Therapeutics’ (12 November 2010), http://www.btc.iitkgp.ernet.in/dey/abstracts/14.pdf
Goswami, Rajdeep, ‘Compliance of TRIPS in Indian Patent Law’ (29 April 2012), http://www.legalservicesindia.com/article/article/compliance-of-trips-in-indian-patent-law-1103-1.html
Giust, John E., ‘Non-compliance with TRIPs by Developed and Developing Countries: Is TRIPs Working?’, Indiana International and Comparative Law Review, 69.95 (1997), 69–97.
Gonzalez, Javier Lopez, Maximillano Mendez Parra, and Anirudh Shingal, ‘TRIPS and Special and Differential Treatment—Revisiting the Case for Derogations in Applying Patent Protection for Pharmaceuticals in Developing Countries’ (Draft Working Paper No. 2011–37, NCCR Trade Regulation, 2011).
Gopakumar, K.M., ‘TRIPS Implementation and Public Health Safeguards’ in South Asian Year Book of Trade and Development, ed. by B.S. Chimni, Mustafizur Rahman, and Linu Mathew Philip (New Delhi: Academic Foundation, 2005), pp. 233–59.
―, ‘Product Patents and Access to Medicines in India: A Critical Review of the Implementation of TRIPS Patent Regime’ The Law and Development Review, 3.2 (2010), 324–68.
Government of India, Directorate General of Foreign Trade, ‘India—The Generics Pharma Capital of the World’ (Pharmaceutical Exports Report, IDMA, Mumbai, India, 2010), http://dgftcom.nic.in
Grace, C., ‘Update on China and India and Access to Medicines’ (Briefing Paper, DFID/HSRC, November 2005), 1–42.
Greene, J., V. Caracelli, and W. Graham, ‘Toward a Conceptual Framework for Mixed-methods Evaluation Designs’, Educational Evaluation and Policy Analysis, 11 (1989), 255–74, http://dx.doi.org/10.3102/01623737011003255
Grover, Anand, Anti-competitive Practices in Patent Licensing Arrangements and the Scope of Competition Law/Policy in Dealing with them (AMTC, National Workshop on Patent and Public Health, Ministry of Health, India, 11 April 2005).
Guell, Robert C., and Marvin Fischbaum, ‘Toward Allocative Efficiency in the Prescription Drug Industry’, Milbank Quarterly, 73.2 (1995), 213–30, http://dx.doi.org/10.2307/3350257
Gupta, Amit Sen, ‘Should Drug Prices be Controlled?’, Economic Times (6 August 2002), http://articles.economictimes.indiatimes.com/2002-08-06/news/27340990_1_drug-prices-price-controls-drug-companie
Gupta, V.K., ‘Traditional Knowledge Documentation and Defensive Protection: An Example from India’ (June 2011), http://www.wipo.int/edocs/mdocs/tk/en/wipo_tk_mct_11/wipo_tk_mct_11_ref_t_5_1.pdf
―, Intellectual Property and Sustainable Development: Documentation and Registration of TK and Traditional Cultural Expressions (12 December 2011), http://www.wipo.int/edocs/mdocs/tk/en/wipo_tk_mct_11/wipo_tk_mct_11_ref_t_5_1.pdf
Haider, Shawkat, ‘Access to Medicines for All’, Dhaka Tribune (20 November 2015), http://www.dhakatribune.com/op-ed/2015/nov/20/access-medicine-all
Hansen, Emily, and Clarissa Hughes, Interviews in Qualitative Research, The Primary Health Care Research, Evaluation and Development Strategy, University of Tasmania (11 September 2009).
Hart, H.L.A., The Concept of Law (Oxford: Oxford University Press, 1961).
Hasan, Nazmul, ‘National Case Studies on the Institutional Framework and Procedures Regulating Access to Pharmaceutical Products Needed to Address Public Health Problems’ (Dhaka, Bangladesh, 2000).
―, ‘Post 2005: Great Time ahead for Exports’, Pharmabiz (27 January 2005), http://www.pharmabiz.com/article/detnews.asp?articleid=25953§ionid=50&z=y
―, ‘Bangladesh—An Emerging Country for Generics’ (12 June 2010), http://www.jacobfleming.com/buxus/docs/downloads/case-study-smgenerics-nazmul-hassan-finalapproed.pdf
―, ‘Future Prospects of Pharmaceutical Industry in Bangladesh’ (2010), http://documents.mx/documents/future-prospects.html
Hasina, Sheikh, Prime Minister of Bangladesh, ‘Speech to the Sixty-fourth World Health Assembly’ (May 17 2011), http://www.who.int/mediacentre/events/2011/wha64/sheikh_hasina_speech_20110517/en/index.html
Hassett, Kevin A., Price Controls and the Evolution of Pharmaceutical Markets (American Enterprise Institute, 2004), http://www.who.int/intellectual
property/news/en/Submission-Hassett.pdf
Hawkins, Loraine, ‘WHO/HAI Project on Medicine Prices and Availability Review Series on Pharmaceutical Pricing Policies and Interventions’ (Working Paper No. 4, Competition Policy, May 2011).
Helfer, L.R., ‘Towards a Human Rights Framework for Intellectual Property’, UC Davis Law Review, 40.3 (2007), 971–1020.
Heller, M.A., and R.S. Eisenberg, ‘Can Patents Deter Innovation? The Anti-commons in Biomedical Research’, Science, 280 (1998), 698–701, http://dx.doi.org/10.1126/science.280.5364.698
Hepburn, Jonathan, ‘A TRIPS Agenda for Development: Meeting Food, Health and Biodiversity Needs’ (a report of the conference organized by The Netherlands Ministry of Foreign Affairs and The Quaker United Nations Office [QUNO], 2001).
Hestermeyer, Holger, Human Rights and the WTO: The Case of Patents and Access to Medicines (Oxford: Oxford University Press, 2007), http://dx.doi.org/10.1093/acprof:oso/9780199552177.003.0001
Hodges, David A., ‘Industry-University Cooperation, and the Emergence of Start-up Companies’ (Public Symposium at Research Institute of Economy, Trade, and Industry, Tokyo, December 2011), http://www.rieti.go.jp/en/events/01121101/Hodges_final.pdf
Hoekman, Bernard, and Michel Kosteki, The Political Economy of the World Trading System (Oxford: Oxford University Press, 1995), http://dx.doi.org/10.1093/019829431x.001.0001
Hoen, Ellen T., The Global Politics of Pharmaceutical Monopoly Power (Diemen: AMB Publishers, 2009).
Hold, Arno, and Mercurio, Bryan Christopher, ‘Transitioning to Intellectual Property: How Can the WTO Integrate Least Developed Countries into TRIPS?’ (Working Paper No. 2012/37, World Trade Institute [WTI], October 2012).
Hollis, Aidan, ‘An Efficient Reward System for Pharmaceutical Innovation’ 6 (10 June 2004) (unpublished manuscript), http://www.who.int/intellectual
property/news/Submission-Hollis6-Oct.pdf
Hossain, Shakhawat, ‘No Enforcement of Laws on Food Adulteration, Children, Fair Trade’, The New Age (19 May 2014), http://newagebd.net/12634/no-enforcement-of-laws-on-food-adulteration-children-fair-trade/#sthash.IMYI3DvK.dpuf
Huberman, Michael, and Matthew B. Miles (eds.), The Qualitative Researcher’s Companion (London: Sage, 2002), http://dx.doi.org/10.4135/9781412986274
Hutchinson, Terry, and Nigel Duncan, ‘Defining What We Do—Doctrinal Legal Research’ (Australian Law Teachers Conference, 2010).
Imam, K.H., ‘Some Aspects of the Foreign Trade Policies of Bangladesh’, in The Economic Development of Bangladesh Within a Socialist Framework, ed. by E.A.G. Robinson and Keith Griffin (New York: Halsted Press, 1974), pp. 289–308, http://dx.doi.org/10.1007/978-1-349-02363-9_11
Islam, Mohammad Towhidul, ‘TRIPS Agreement and Public Health: Implications and Challenges for Bangladesh’, International Trade Law and Regulation, 17.1 (2011), 10–39.
Islam, Muinul, Prantio Punjibadi Rashtro O Onunnayan Proshongo (Dhaka: Pa[yrus Publishers, 2003).
Jackson, John H., The Jurisprudence of GATT and the WTO (Cambridge: Cambridge University Press, 2000).
Jain, Dipika, ‘Access to Drugs in India: Exploration of Compulsory Licensing as an Effective Tool’ (LLM Paper, Harvard Law School, 2009).
Jayashree, Watal, Intellectual Property Rights in the WTO and Developing Countries (Oxford: Oxford University Press, 2001).
Johnson, R. Burke, and Anthony J. Onwuegbuzie, ‘Mixed Methods Research: A Research Paradigm Whose Time Has Come’, Educational Researcher, 33.7 (2004), 14–26, http://dx.doi.org/10.3102/0013189x033007014
Jones, Emily, ‘Signing Away the Future: How Trade and Investment Agreements Between Rich and Poor Countries Undermine Development’ (Oxfam Briefing Paper No. 101, March 2007), http://www.oxfam.org/sites/www.oxfam.org/files/Signing Away the Future.pdf
Jones, M.L., ‘Using Software to Analyse Qualitative Data’, Malaysian Journal of Qualitative Research, 1.1 (2007), 64–76.
Joseph, Reji K., ‘India’s Trade in Drugs and Pharmaceuticals: Emerging Trends, Opportunities and Challenges’ (Discussion Paper No. 159, Research Information System for Developing Countries, 2009).
Kalam, Abul, ‘Challenges of the Age of Globalization’, Regional Studies, 19.4 (2001), 35–51.
Kalam, Abul, Globalisation and Bangladesh, Dhaka (Dhaka: Palok, 2002).
Kapczynski, Amy, Samantha Chaifetz, Zachary Katz, and Yochai Benkler, ‘Addressing Global Health Inequities: An Open Licensing Approach for University Innovations’, Berkeley Technology Law Journal, 20 (2005), 1032–113.
Kathuria, Sanjay and Mariem Mezghenni Malouche, ‘Toward New Sources of Competitiveness in Bangladesh: Key Insights of the Diagnostic Trade Integration Study’ (2016), https://openknowledge.worldbank.org/handle/
10986/22712
Khan, Jashim Uddin, ‘New Patent Rights of Drug Suspended’, The Daily Star (14 March 2008), http://www.thedailystar.net/news-detail-27621
Khan, Md Farhad Hossain, ‘IP Administration and Enforcement System: Towards Modernisation of IP Protection in Bangladesh and A Comparative Analysis of IP Administration between Japan and Bangladesh’ (a fellowship report, Tokyo Institute of Technology, 1 April to 30 September 2004).
―, and Yoshitoshi Tanaka, ‘IP Administration and Enforcement System towards Modernization of IP Protection in Bangladesh and a Comparison of IP Situation between Japan and Bangladesh’, IP Management Review, 2 (2004), 1–15.
Khan, Zorina, ‘Premium Inventions: Patents and Prizes as Incentive Mechanisms in Britain and the United States, 1750–1930’ (24 November 2010), http://people.hss.caltech.edu/~jlr/courses/questions/khan.pdf
Khor, Martin, ‘Rethinking Intellectual Property Rights and TRIPS’, in Global Intellectual Property Rights—Knowledge, Access and Development, ed. by Peter Drahos and Ruth Mayne (New York: Palgrave Macmillan, 2002), pp. 201–13.
Klug, Heinz, ‘Pharmaceutical Production and Access to Essential Medicines in South Africa’, in Intellectual Property, Pharmaceuticals and Public Health—Access to Drugs in Developing Countries, ed. by Kenneth C. Shadlen, Samira Guennif, Alenka Guzman and N. Lalitha (Cheltenham: Edward Elgar, 2011), pp. 29–55.
Kongolo, T., ‘Public Interest versus the Pharmaceutical Industry’s Monopoly in South Africa’ Journal of World Intellectual Property, 4 (2001), 605–16, http://dx.doi.org/10.1111/j.1747-1796.2001.tb00130.x
Kontic, Sasha, ‘An Analysis of the Generic Pharmaceutical Industries in Brazil and China in the Context of TRIPS and HIV/AIDS’, https://www.law.utoronto.ca/documents/ihrp/HIV_kontic.doc
Krikorian, Gaelle P. and Szymkowiak, Dorota M., ‘Intellectual Property Rights in the Making: The Evolution of Intellectual Property Provisions in US Free Trade Agreements and Access to Medicine’, Journal of Intellectual Property Law, 10 (2007), 388–418.
Kuanpoth, Jakkrit, ‘Intellectual Property Rights and Pharmaceuticals: A Thai Perspective on Prices and Technological Capability’, Thailand Law Journal, 11.2 (2008), 55–84.
―, Patent Rights in Pharmaceuticals in Developing Countries: Major Challenges for the Future (Cheltenham: Edward Elgar, 2010), http://dx.doi.org/10.
4337/9781849808958
Kumar, K. Suresh, ‘Patent Laws and Research Exemption Imperative—Do Scientists Have Enough Freedom to Operate?’, Current Science, 99 (2010), 1488–524.
Kumar, Swarup, ‘Compulsory Licensing Provision under TRIPS: A Study of Roche vs Natco Case in India vis-à-vis the Applicability of the Principle of Audi Alteram Partem’, SCRIPT-ed, 7.1 (2010), 135–54.
Lahouel, Mohamed, and Keith E. Maskus, ‘Competition Policy and Intellectual Property Rights in Developing Countries: Interests in Unilateral Initiatives and a WTO Agreement’ (Paper presented at the WTO/World Bank Conference on Developing Countries in a Millennium Round, 20–21 September 1999).
Lalitha, N., ‘Doha Declaration and Public Health Issues’, Journal of Intellectual Property Rights, 13 (2008), 401–13.
―, ‘TRIPS and Pharmaceutical Industry: Issues and Prospects’ (12 December 2009), http://www.iprsonline.org/ictsd/docs/ResourcesHealthArticleLalitha.doc
―, ‘Access to Indian Generic Drugs: Emerging Issues’, in Intellectual Property, Pharmaceuticals and Public Health, ed. by Kenneth C. Shadlen, Samira Guennif, Alenka Guzman and N. Lalitha (Cheltenham: Edward Elgar, 2011), pp. 225–52, http://dx.doi.org/10.4337/9780857938619.00014
Lall, Sanjaya, ‘Indicators of the Relative Importance of IPRs in Developing Countries’ (UNCTAD-ICTSD Project on IPRs and Sustainable Development, 1 June 2003), http://dx.doi.org/10.7215/ip_ip_20030601b
Lanjouw, Jane O., ‘The Introduction of Pharmaceutical Product Patents in India: “Heartless Exploitation of the Poor and Suffering”?’ (Working Paper No. 6366, Yale University and the NBER, 26 August 1997), http://dx.doi.org/10.3386/w6366
Lee, Thomas H., ‘“Me-too” Products: Friend or Foe?’, New England Journal of Medicine, 350.3 (2004), 211–12, http://dx.doi.org/10.1056/nejm200405133502019
Lee, Ting-Ting, ‘Adopting a Personal Digital Assistant System: Application of Lewin’s Change Theory’, Journal of Advanced Nursing 55.4 (2006), 487–96, http://dx.doi.org/10.1111/j.1365-2648.2006.03935.x
Leesti M. and Pengelly, T., ‘Assessing Technical Assistance Needs for Implementing the TRIPS Agreement in LDCs’ (ICTSD Programme on Intellectual Property Rights and Sustainable Development, International Centre for Trade and Sustainable Development, Geneva, Switzerland 2007).
Lewin, K., ‘Frontiers in Group Dynamics II. Channels of Group Life; Social Planning and Action Research’, Human Relations, 1.1 (1947), 5–40.
Li, Xuan, ‘The Impact of Higher Standards in Patent Protection for Pharmaceutical Industries under the TRIPS Agreement—A Comparative Study of China and India’, The World Economy, 31.10 (2008), 1367–92, http://dx.doi.org/10.1111/j.1467-9701.2008.01133.x
Lorenzi, N.M., R.T. Riley, A.J.C. Blyth, G. Southon, and B.J. Dixon, ‘Antecedents of the People and Organizational Aspects of Medical Informatics: Review of the Literature’, Journal of American Medical Informatics Association, 4.2 (1997), 79–93, http://dx.doi.org/10.1136/jamia.1997.0040079
Love, James, ‘Remuneration Guidelines for Non-voluntary Use of a Patent on Medical Technologies’ (Health Economics and Drugs, TCM series no. 18, 2005), http://www.who.int/medicines/areas/technical_cooperation/WHO
TCM2005.1_OMS.pdf
―, ‘WHO Negotiators Propose Putting off R&D Treaty Discussions until 2016’ (Knowledge Ecology International, 28 November 2012), http://keionline.org/node/1612
Lu, Bingbin, ‘Best Mode Disclosure for Patent Applications: An International and Comparative Perspective’, Journal of Intellectual Property Rights, 16 (2011), 409–17.
Madely, John, Hungry for Trade (London: Zed Books, 2000).
Maggi, Giovanni, and Andres Rodriguez-Clare, ‘The Value of Trade Agreements in the Presence of Political Pressures’, Journal of Political Economy, 106.3 (1998), 574–601, http://dx.doi.org/10.1086/250022
Malpani, Rohit, ‘All Costs, No Benefits: How TRIPS-plus Intellectual Property Rules in the US–Jordan FTA Affect Access to Medicines’, 11 (Oxfam Briefing Paper No. 102, 21 March 2007), http://www.oxfam.org/sites/www.oxfam.org/files/all costs, no benefits.pdf
Mahmud, Wahiduddin, ‘Has Bangladesh Gained from its LDC status?’ The Daily Star (28 May 2010).
Mansfield, Edwin, ‘Patents and Innovation: An Empirical Study’, Management Science, 32.2 (1986), 173–81, http://dx.doi.org/10.1287/mnsc.32.2.173
―, ‘Intellectual Property Protection, Direct Investment and Technology Transfer: Germany, Japan and the United States’ (Discussion Paper No. 27, World Bank and International Finance Corporation, 1995).
Martinez, Ana Paula, ‘Abuse of Dominance: The Third Wave of Brazil’s Antitrust Enforcement?’, Competition Law International, 9 (2013), 168–81.
Maskus Keith E. and Denise Eby-Konan, ‘Trade-related Intellectual Property Rights: Issues and Exploratory Results’, in Analytical and Negotiating Issues in the Global Trading System, ed. by Alan V. Deardorff and Robert M. Stern (Ann Arbor, MI: University of Michigan Press 1994), pp. 401–54.
―, S.M. Dougherty, and A. Mertha, ‘Intellectual Property Rights and Economic Development in China’, in Intellectual Property and Development: Lessons from Recent Economic Research, ed. by C. Fink and K.E. Maskus (Washington, DC: World Bank and Oxford University Press, 2005), http://dx.doi.org/10.1596/0-8213-5772-7
Masum, H., and R. Harris, Open Source for Neglected Diseases: Magic Bullet or Mirage? (Washington, DC: Results for Development Institute, 2011).
Maurer S.M., A. Rai, and A. Sali, ‘Finding Cures for Tropical Diseases: Is Open Source an Answer?’, PLoS Med, 1.3 (2004), e56, http://dx.doi.org/10.1371/journal.pmed.0010056
May, Christopher and Susan K. Sell, Intellectual Property Rights: A Critical History (Boulder, CO: Lynne Rienner Pub. 2005).
Maynard, Alan, and Karen Bloor, ‘Dilemmas in Regulation of the Market for Pharmaceuticals’, Health Affairs, 22.3 (2003), 31–41, http://dx.doi.org/10.1377/hlthaff.22.3.31
Mazumdar, Satyajeet, ‘Bolar Provisions (Patents): Position in Different Countries and Case Laws’ (24 December 2009), http://knol.google.com/k/satyajeet-mazumdar/bolar-provisions-patents/3cc0jmgzt3vqu/6 [accessed on December 2015].
McConville, Mike, and Hong Chui Wing (eds.), Research Methods for Law (Edinburgh: Edinburgh University Press, 2007).
McKinsey and Company, ‘Bangladesh’s Ready-made Garments Landscape: The Challenge of Growth’ (2011) http://www.mckinsey.de/sites/mck_files/files/2011_McKinsey_Bangladesh.pdf
Mercurio, Bryan, ‘Resolving the Public Health Crisis in the Developing World: Problems and Barriers of Access to Essential Medicines’, Northwestern University Journal of International Human Rights, 5 (2006), 1–40, http://dx.doi.org/10.2139/ssrn.980175
Mittal, Anshull, ‘Patent Linkage in India: Current Scenario and Need for Deliberation’, Journal of Intellectual Property Rights, 15 (2010), 187–96.
Moon S., J. Bermudez, E. ‘t Hoen, ‘Innovation and Access to Medicines for Neglected Populations: Could a Treaty Address a Broken Pharmaceutical R&D System?’ PLoS Med 9.5 (2012), e1001218 http://dx.doi.org/10.1371/journal.pmed.1001218
Moon, Suerie, ‘Does Article 66.2 Encourage Technology Transfer to LDCs? An Analysis of Country Submissions to the TRIPS Council (1999–2007)’ (UNCTAD/ICTSD Project on IPRs, and Policy Brief Number 2 2008).
Morton, Fiona M. Scott ‘The Problems of Price Controls’, Regulation 50 (2001), http://object.cato.org/sites/cato.org/files/serials/files/regulation/2001/4/morton.pdf
Mueller, Janice, ‘The Tiger Awakens: The Tumultuous Transformation of India’s Patent System and The Rise of Indian Pharmaceutical Innovation’, University of Pittsburgh Law Review, 68.49 (2007), 491–641, http://dx.doi.org/10.5195/lawreview.2007.79
Mugambe, Lydia, ‘The Exception to Patent Rights under the WTO-TRIPS Agreement: Where is the Right to Health Guaranteed?’ (unpublished LLM thesis, University of Western Cape, South Africa, 2002).
Murshed, Md Mahboob, ‘Trips Agreement and Patenting of Pharmaceutical Products’, The Daily Star (3 August 2006), http://archive.thedailystar.net/law/2006/08/03/index.htm (accessed by searching the Internet Archive index).
Musungu, Sislu F., Susan Villanueva, and Roxana Blasetti, Utilizing TRIPS Flexibilities for Public Health Protection through South-South Regional Framework (South Centre, 2004).
Nair, Manisha Singh, ‘Rationality of a Patent Pool’ (12 December 2009), http://www.ipfrontline.com/depts/article.asp?id=22735&deptid=6
Nard, Craig Allen, ‘American Patent Law: With European and TRIPS Comparative Perspectives, Materials’ (prepared for WIPO-Turin LLM Program Intellectual Property Law, 18–22 September 2006).
Narayan, S.,‘Some Approaches to Pricing Controls for Patented Drugs in India’, ISAS Insights, 41 (1 December 2008), http://mercury.ethz.ch/serviceengine/Files/ISN/94707/ipublicationdocument_singledocument/f8515305-e6a3-4b13-9ba4-27d9ba38b937/en/42.pdf
Nwokike, Jude., and H.L. Choi, ‘Assessment of the Regulatory Systems and Capacity of the Directorate General for Drug Administration in Bangladesh’ (submitted to the US Agency for International Development by the Systems for Improved Access to Pharmaceuticals and Services Program, Arlington, VA: Management Sciences for Health, 2012).
Oh, Cecilia, and Sisule Musungu, ‘The Use of Flexibilities in TRIPS by Developing Countries: Can They Promote Access to Medicines?’ (Commission on Intellectual Property Rights, Innovation and Public Health, Study 4C, 12 October 2010), http://www.who.int/intellectualproperty/studies/TRIPSFLEXI.pdf
Oliveira, Bermudez, and Egleubia Oliveira, ‘Expanding Access to Essential Medicines in Brazil: Recent Regulation and Public Policies’, in Intellectual Property in the Context of the WTO TRIPS Agreement: Challenges for Public Health, ed. by Jorge A.Z. Bermudez and Maria Auxiliadora Oliveira (Rio de Janeiro, Center for Pharmaceutical Policies, 2004), pp. 129–52.
Oliveira, Maria Auxiliadora, ‘Brazilian Intellectual Property Legislation’, in Intellectual Property in the Context of the WTO TRIPS Agreement: Challenges for Public Health, ed. by Jorge A.Z. Bermudez and Maria Auxiliadora Oliveira (Rio de Janeiro, Center for Pharmaceutical Policies, 2004) (2005), 153–62.
Ostry, Sylvia, ‘Intellectual Property Protection in the WTO: Misuses in the Millennium Round’ (Fraser Institute Conference, Santiago, 19 April 1999).
Oxfam, ‘Cut the Cost–Patent Injustice: How World Trade Rules Threaten the Health of Poor People’ (8 October 2001), http://www.iatp.org/documents/cut-the-cost-patent-injustice-how-world-trade-rules-threaten-the-health-of-poor-people
―, Make Vital Medicine Available for People—Bangladesh (25 July 2010), http://policy-practice.oxfam.org.uk/publications/make-vital-medicines-available-
for-poor-people-bangladesh-112437
Palmer, V.V., ‘From Lerotholi to Lando: Some Examples of Comparative Law Methodology’, American Journal of Comparative Law, 53 (2005), 1–29, http://dx.doi.org/10.2202/1535-1653.1126
Planning Commission of India, Report of the Working Group on Drugs and Pharmaceuticals for the Eleventh Five Year Plan, 2007–2012 (2006), http://planningcommission.nic.in/aboutus/committee/wrkgrp11/wg11_pharma.pdf
Plessis, Esmé du Report Q.202 (South Africa), AIPPI, https://www.aippi.org/download/commitees/202/GR202south_africa.pdf
Pokorski da Cunha, Ulrike, ‘Study on the Viability of High Quality Drugs Manufacturing in Bangladesh’ (commissioned by Deutsche Gesellschaft für Technische Zusammenarbeitm, 2007), https://www.unido.org/fileadmin/user_media/Services/PSD/BEP/en-high-quality-drugs-bangladesh-2007.pdf
Polanvyi, Michael, ‘Patent Reform’, Review of Economic Studies, 11 (1944), 61–76, http://dx.doi.org/10.2307/2295967
Polit, D.F., and B.P. Hungler, Nursing Research—Principles and Methods, 6th edn. (Philadelphia: Lippincott Williams & Wilkins, 1999).
Primo-Braga, C.A., and C. Fink, ‘The Relationship between Intellectual Property Rights and Foreign Direct Investment’, Duke Journal of Comparative and International Law, 9 (1998), 163–87.
Quat, Pham Hong, ‘How to Comply with the TRIPS and WTO Law—The New Challenges to Vietnam’s Patent Legislation from WTO Dispute Settlement Practice’ (Nagoya University, Japan, 2007).
Rai, Rajnish Kumar, ‘Patentable Subject Matter Requirements: An Evaluation of Proposed Exclusions to India’s Patent Law in Light of India’s Obligations under the TRIPS Agreement and Options for India’, Chicago-Kent Journal of Intellectual Property, 8 (2008), 41–84.
Raghavan, Chakravarthi, ‘US to Withdraw TRIPS Dispute against Brazil’, http://www.twn.my/title/withdraw.htm
Ram, Prabhu, ‘India’s New “Trips-compliant” Patent Regime between Drug Patents and the Right to Health’, Chicago-Kent Journal of Intellectual Property, 5 (2006), 195–206.
Reddy, K.C. (ed.), WTO and Implications for South Asia (New Delhi: Serials Publications, 2006).
Reichman, J.H., ‘From Free Riders to Fair Followers: Global Competition under the TRIPS Agreement’, New York University Journal of International Law and Politics, 29 (1997), 11–93.
―, ‘Universal Minimum Standards of Intellectual Property Protection under the TRIPs Component of the WTO Agreement’, in Intellectual Property and international Trade: TRIPs Agreement, ed. by Abdulqawi A. Yusuf, Carlos M. Correa (Kluwer Law International, 1998).
Robson, Colin, Real World Research: A Resource for Social Scientists and Practitioner Researchers (Oxford: Blackwell, 1993).
Rossman, G., and B. Wilson, ‘Numbers and Words Revisited: Being “Shamelessly Eclectic”’, Evaluation Review, 9.5 (1991), 627–43, http://dx.doi.org/10.1007/bf01098947
Roumet, Rachel, ‘Access to Patented Anti-HIV/AIDS Medicine: The South African Experience’, European Intellectual Property Review, 3 (2010), 137–41.
Ruse-Khan, Henning Grosse and Thomas Jaeger, ‘Policing Patents Worldwide? EC Border Measures Against Transiting Generic Drugs Under EC and WTO Intellectual Property Regimes’, International Review of Intellectual Property and Competition Law, 40.5 (2009), 502–38.
Russell, Sabin, ‘New Crusade to Lower AIDS Drug Costs’, The San Francisco Chronicle (24 May 1999).
Saad, K., and Safwan, ‘An Overview of the Pharmaceutical Sector in Bangladesh’ (Brac EPL Study, Dhaka, Bangladesh, May 2012).
Sampath, Padmashree Gehl, ‘Economic Aspects of Access to Medicines Post-2005: Product Patent Protection and Emerging Firm Strategies in the Indian Industry’ (background study of the Commission on Intellectual Property Rights, Innovation and Public Health, WHO, 2005).
―, Economic Aspects of Access to Medicine after 2005 (UNU-MERIT, 2005, 22), http://www.who.int/intellectualproperty/studies/PadmashreeSampathFinal.pdf
―, ‘India’s Product Patent Protection Regime: Less or More of “Pills for the Poor”?’, The Journal of World Intellectual Property, 9.6 (2006), 694–702, http://dx.doi.org/10.1111/j.1422-2213.2006.00308.x
―, ‘Intellectual Property in Least Developed Countries: Pharmaceutical, Agro-processing, and Textiles and RMG in Bangladesh’ (study prepared for UNCTAD as a background Paper for The Least Developed Countries Report, Geneva: UNCTAD, 2007a).
―, ‘Innovation and Competitive Capacity in Bangladesh’s Pharmaceutical Sector’ (Working Paper Series, Paper No. 2007–031, United Nations University, Maastricht Economic and Social Research and Training Centre [UNU-MERIT], September 2007b).
Scherer, F.M., and Jayashree Watal, ‘Post-TRIPS Options for Access to Patented Medicines in Developing Countries’ (Working Paper Series, Paper No. WG4:1, Commission on Macroeconomics and Health [CMH]), http://library.cphs.chula.ac.th/Ebooks/HealthCareFinancing/WorkingPaper_WG4/WG4_1.pdf
Scherer, F.M., S.E. Herzstein, A.W. Dreyfoos, W.G. Whitney, O.J. Bachman, C.P. Pesek, C.J. Scott, T.G. Kelly, and J.J. Galvin, Patents and the Corporation: A Report on Industrial Technology under Changing Public Policy (Cambridge, MA: Harvard University Press, 1959).
Sell, Susan, ‘The Global IP Upward Ratchet, Anti-counterfeiting and Piracy Enforcement Efforts: The State of Play’ (PIJIP Research Paper Series. No. 15, American University Washington College of Law, 2010), http://digitalcommons.wcl.american.edu/research/15
―, ‘TRIPS Was Never Enough: Vertical Forum Shifting, FTAS, ACTA and TPP’, Journal of Intellectual Property Law, 18 (2011), 447–78, http://infojustice.org/download/tpp/tpp-academic/Sell - TRIPS Was Never Enough - June 2011.pdf
Sen, Pronob, ‘Taskforce to Explore Options other than Price Control for Achieving the Objective of Making Available Life-saving Drugs at Reasonable Prices’ (Department of Chemicals and Petrochemicals, India, 2005).
Sengupta, Arghya, ‘Parallel Imports in the Pharmaceutical Sector: Must India be More Liberal’, Journal of Intellectual Property Rights, 12 (2007), 400–09.
Shadlen, Kenneth C., ‘The Politics of Patents and Drugs in Brazil and Mexico: The Industrial Bases of Health Policies’, Comparative Politics, 42.1 (2009), 41–58, http://dx.doi.org/10.4337/9780857938619.00012
Shanker, Archana, and Neeti Wilson, ‘The Patent Opposition System in India’, IAM Magazine (8 July 2010), http://www.iam-media.com/Intelligence/IP-Value-in-the-Life-Sciences/2008/Articles/The-patent-opposition-system-in-India
Shanker, Daya, ‘Fault Lines in the World Trade Organization: An Analysis of the TRIPS Agreement and Developing Countries’ (unpublished doctoral thesis, University of Wollongong, 2005).
Shanker, Daya, ‘India, the Pharmaceutical Industry and the Validity of TRIPS’, The Journal of World Intellectual Property, 5.3 (2002), 351–70, http://dx.doi.org/10.1111/j.1747-1796.2002.tb00162.x
―,‘Brazil, Pharmaceutical Industry and the WTO’, Journal of World Intellectual Property, 5 (2002), 53–70, http://dx.doi.org/10.1111/j.1747-1796.2002.tb00148.x
Sharma, Animesh, ‘Data Exclusivity with Regard to Clinical Data’, The Indian Journal of Law and Technology, 3 (2007), 82–104.
Shiva, Vandana, Protect or Plunder (London: Zed Books, 2001).
Siddiqui, Hafiz G.A., ‘WTO and Economic Security: Bangladesh Perspectives’ (Paper presented at the BIISS Workshop, 29 February 2000).
Simons, J.J., ‘Cooperation and Coercion: The Protection of Intellectual Property in Developing Countries’, Bond Law Review, 11.1 (1999), 59–97.
Smarzynska, B., ‘The Composition of Foreign Direct Investment and Protection of Intellectual Property Rights: Evidence from Transition Economies’, European Economic Review, 48 (2004), 39–62, http://dx.doi.org/10.1016/s0014-2921(02)00257-x
South Centre and CIEL, ‘Extension of the Transition Period for LDCs: Flexibility to Create a Viable Technological Base or Simply (A Little) More Time?’, Intellectual Property Quarterly Update (2006), 1–15.
Sparrow, M. The Regulatory Craft: Controlling Risks, Managing Problems and Managing Compliance (Washington, DC: The Brookings Institution, 2000).
Srinivasan, S., ‘How TRIPS Benefits Indian Industry and How It May Not Benefit the Indian People’, Indian Journal of Medical Ethics, 5.2 (2008), 66–69.
St Martin, Anne, ‘The Impact of Trade Related Aspects of Intellectual Property Rights (TRIPS) on Access to Essential Medicines in the Developing World’ (a research report submitted to Worcester Polytechnic Institute, 1 May 2006).
Staiger, Robert W., and Guido Tabellini, ‘Do GATT Rules Help Governments Make Domestic Commitments?’, Economics and Politics, 11.2 (1999), 109–44, http://dx.doi.org/10.1111/1468-0343.00055
Staiger, Robert W., ‘The World Trade Organization’, in The New Palgrave Dictionary of Economics, ed. by Steven N. Durlauf and Lawrence E. Blume, 2nd edn. (London: Palgrave, 2006), pp. 777–80, http://dx.doi.org/10.1057/9780230226203.1843
State Intellectual property Office (SIPO) of the Peoples Republic of China (PRC), ‘Patent Law of the Peoples Republic of China’, http://english.sipo.gov.cn/laws/lawsregulations/201101/t20110119_566244.html
Stiglitz, Joseph E. ‘Scrooge and Intellectual Property Rights’, British Medical Journal 333 (2006), 1279–80, http://dx.doi.org/10.1136/bmj.39048.428380.80
―, The Price of Inequality: How Today’s Divided Society Endangers our Future (New York: Norton, 2012).
Subramanian, A., ‘Putting Some Number on the TRIPS Pharmaceutical Debate’, International Journal of Technology Management, 10 (1995), 252–68.
Sussex, Jon, Koonal K. Shah, and Jim Butler, ‘The Publicly Funded Vaccines Market in Australia’ (Consulting Report No. 10/02, Office of Health Economics [OHE], 25 October 2010).
Suthersanen, Uma, ‘Utility Models and Innovation in Developing Countries’ (5–7 February 2006), http://unctad.org/en/Docs/iteipc20066_en.pdf
Swarns, Rachel L. ‘Drug Makers Drop South Africa Suit over AIDS Medicine’, The New York Times (20 April 2001).
Taylor, C.T., and Z.A. Silberston, The Economic Impact of the Patent System (Cambridge: Cambridge University Press, 1973).
Teljeur, Ethel, Intellectual Property Rights in South Africa: An Economic Review of Policy and Impact (Braamfontein: The Edge Institute, South Africa, 2003).
Third World Network Brief, ‘WHO: WHA strengthens WHO’s mandate on IP and Health’ (27 May 2008), http://www.twn.my/title2/health.info/2008/twnhealthinfo20080602.htm
Tomar, David K., ‘A Look into the WTO Pharmaceutical Patent Dispute between the United States and India’, Wisconsin International Law Journal, 17 (1999), 579–603.
Tomlinson, Catherine and Lotti Rutter, ‘The Economic and Social Case for Patent Law Reform in South Africa’ (2014), http://www.tac.org.za/sites/default/files/The Economic and Social Case for Patent Law Reform in South Africa.pdf
Trebilcock, Michael J., and Robert Howse, The Regulation of International Trade, 2nd edn (Abingdon and New York: Routledge, 1999).
Trouiller, Patrice, P. Olliaro, E. Torreele, J. Orbinski, R. Laing, and N. Ford, ‘Drug Development for Neglected Diseases: A Deficient Market and a Public-health Policy Failure’, Lancet, 359 (2002), 2188–94, http://dx.doi.org/10.1016/s0140-6736(02)09096-7
Uddin, Khawaza Main, ‘Govt Inching Closer Towards Signing TIFA with US’, Business Info Bangladesh (7 November 2009), https://web.archive.org/web/20101120054050/http://bizbangladesh.com/business-news-2758.php (accessed by searching the Internet Archive index).
Uddin, S., M. Anowar, ‘TRIPS Waiver but Why the Pharmaceutical Medicines Hard to Get in Bangladesh’ (project report submitted to Roskilde University, 2008), http://rudar.ruc.dk/bitstream/1800/4060/3/Project_WTO.pdf
United Nations Conference on Trade and Development (UNCTAD)/World Trade Organization (WTO), Bangladesh: Supply and Demand Survey on Pharmaceuticals and Natural Products, International Trade Centre (September 2005).
UN, Report of the Open Working Group of the General Assembly on Sustainable Development Goals, Resolution 68/970 (2014).
United States Trade Representative (USTR), Special 301 Report, 2009 (10 July 2010), https://ustr.gov/about-us/policy-offices/press-office/reports-and-publications/2009/2009-special-301-report
UNCTAD-ICTSD, Resource Book on TRIPS and Development (Cambridge: Cambridge University Press, 2005), http://dx.doi.org/10.1017/cbo9780511511363
UNCTAD-ICTSD, WTO Public Symposium, ‘Disclosure Requirements: Incorporating the CBD Principles in the TRIPS Agreement on the Road to Hong Kong’, p. 1 (21 April 2005), http://ictsd.org/downloads/2008/12/meeting-report.pdf
Yamin, Farhana, ‘Globalisation and the International Governance of Modern Biotechnology: IPRs, Biotechnology and FoodSecurity’, Foundation for International Environmental Law and Development, http://www.sristi.org/mdpipr2004/other_readings/OR 42.pdf
VanDuzer, Tony, ‘TRIPS and Pharmaceutical Industry in Bangladesh: Towards a National Strategy’ (Paper No. 24, CPD, April 2003), http://www.bdresearch.org/home/attachments/article/nArt/TRIPS_and_the_Pharmaceutical_Industry_in_Bangladesh.pdf
Vaver, David, ‘Intellectual Property Today: Of Myths and Paradoxes’, Canadian Bar Review, 69 (1990), 98–126.
Volansky, M., ‘Achieving Global Health: A Review of the World Health Organization’s Response’, Tulsa Journal of Comparative International Law, 10 (2002), 223–59.
Watal, J., ‘Introducing Product Patents in the Indian Pharmaceutical Sector: Implications for Prices and Welfare’, World Competition, 20 (1999), 5–21.
―, ‘Pharmaceutical Patents, Prices and Welfare Losses: Policy Options for India under the WTO TRIPS Agreement’, The World Economy, 23 (2000), 733–52.
Wei, Marlynn, ‘Should Prizes Replace Patents? A Critique of the Medical Innovation Prize Act of 2005’, Boston University Journal of Science and Technology Law, 13.1 (2007), 3–21.
Werner, Wendy J., ‘Micro-insurance in Bangladesh: Risk Protection for the Poor?’, Journal of Health, Population and Nutrition, 27 (2009), 563–73.
Wendt, Rasmus Alex, ‘TRIPs in India’ (unpublished doctoral thesis, Roskilde University, 2007).
World Bank, ‘World Development Report: Building Institutions for Markets’ 147 (2002), https://openknowledge.worldbank.org/handle/10986/5984
―, ‘Public and Private Sector Approaches to Improving Pharmaceutical Quality in Bangladesh’, 15 (March 2008), http://www-wds.worldbank.org/external/default/WDSContentServer/WDSP/IB/2008/09/01/000334955_20080901071115/Rendered/PDF/451900NWP0Box31uality0no2301PUBLIC1.pdf
World Health Organization (WHO), Macroeconomics and Health: Investing in Health for Economic Development (Commission on Macroeconomics and Health, 2001), http://www.who.int/pmnch/knowledge/topics/2001_who_cmh/en/
―, Globalization and Access to Drugs: Implications of the WTO/TRIPS Agreement, Health Economic and Drugs Series, No. 007 (1998), http://apps.who.int/medicinedocs/en/d/Jwhozip35e/3.5.html
―, ‘Counterfeit Drugs. Guidelines for the Development of Measures to Combat Counterfeit Drugs’ (1999), http://apps.who.int/medicinedocs/en/d/Jh1456e/
―, Public–Private Roles in the Pharmaceutical Sector: Implications of Equitable Access and Rational Drug Use (2002), http://apps.who.int/medicinedocs/en/d/Jwhozip27e/
―, Drugs and Money Prices, Affordability and Cost Containment, ed. by M.N.G. Dukes, C.P. de Joncheere et al. (2003), http://www.euro.who.int/__data/assets/pdf_file/0011/96446/e79122.pdf
―, Resolution of the World Health Assembly: Intellectual Property Rights, Innovation and Public Health, WHA56.27 (Geneva: WHO, 2003), http://www.who.int/intellectualproperty/documents/en/
―, ‘Intellectual Property Protection: Impact on Public Health’, WHO Drug Information, 19 (2005), 236, 240, http://apps.who.int/medicinedocs/pdf/s7918e/s7918e.pdf
―, ‘Public Health, Innovation, and Intellectual Property Rights: Report of the Commission on Intellectual Property Rights, Innovation and Public Health’, 133 (2006) (the “CIPIH Report”), http://www.who.int/intellectualproperty/documents/thereport/ENPublicHealthReport.pdf
―, Public Health, Innovation, Essential Health Research and Intellectual Property Rights: Towards a Global Strategy and Plan of Action A59/55 (Geneva: WHO, 2006), http://apps.who.int/gb/archive/pdf_files/WHA59/A59_55-en.pdf
―, ‘[Global Framework on] Essential Health Research and Development’, in Executive Board, 117th Session, Resolutions, Decisions, and Annexes 20 (27 January 2006), http://apps.who.int/gb/ebwha/pdf_files/EB117-REC1/B117_REC1-en.pdf
―, ‘Intellectual Property Rights and Access to Medicines: A South-East Asia Perspective on Global Issues’ (2008), http://apps.searo.who.int/pds_docs/B3468.pdf
―, ‘Proposal by Bolivia, Suriname and Bangladesh: Prizes as a Reward Mechanism for New Cancer Treatments and Vaccines in Developing Countries’ 1 (15 April 2009), http://www.who.int/phi/Bangladesh_Bolivia_Suriname_CancerPrize.pdf
―, ‘Promoting Access to Medical Technologies and Innovation: Intersections between Public Health, Intellectual Property and Trade’, 53 (2012), http://www.wto.org/english/res_e/booksp_e/pamtiwhowipowtoweb13_e.pdf
WHO, KEI, Intergovernmental Working Group Submission on Collective Management of Intellectual Property, ‘The Use of Patent Pools to Expand Access to Needed Medical Technologies’, 3 (30 September 2007), http://www.who.int/phi/public_hearings/second/contributions_section2/Section2_ManonRess-PatentPool.pdf
WHO, WHA Executive Board Res., ‘Revised Drug Strategy’ (EB 101/R.24), 2 (27 January 1998), http://apps.who.int/gb/archive/pdf_files/EB101/pdfangl/angr24.pdf
WHO and WTO, Joint study by the WHO and the WTO Secretariats on ‘WTO Agreements and Public Health’ (2002), p. 106, https://www.wto.org/english/res_e/booksp_e/who_wto_e.pdf
World Intellectual Property Organization (WIPO), ‘Paris Convention for Protection of Industrial Property of 20 March 1883, as revised in Brussels on 14 December 1900, in Washington on 2 June 1911, at The Hague on 6 November 1925, in London on 2 June 1934, in Lisbon on 31 October 1958 and in Stockholm on 14 July 1967’, http://www.wipo.int/treaties/en/text.jsp?file_id=288514
―, Standing Committee on the Law of Patents, Exclusions from Patentable Subject Matter and Exceptions and Limitations to the Rights (2009).
―, Lei No. 9.279 art. 24, de 14 de maio de 1996, Diario Oficial Da Uniao [DOU] de 15.05.1996. (Braz.), translated in Brazil: IndustrialProperty Law, 14/05/1996, No. 9.279, http://www.wipo.int/wipolex/en/details.jsp?id=515
―, Study on Patent Related Flexibilities in the Multilateral Legal Framework and Their Legislative Implementation at the National and Regional Levels (WIPO Committee on Development and Intellectual Property, Fifth Session, WIPO Secretariat, Geneva, 26–30 April, 2010).
WIPO, WHO and World Trade Organisation (WTO), Trilateral Study, Promoting Access to Medical Technologies and Innovation—Intersections between Public Health, Intellectual Property and Trade (2013).
WTO, ‘Agreement on Trade-related Aspects of Intellectual Property Rights, Apr. 15, 1994, Marrakesh Agreement Establishing the World Trade Organization, Annex 1C, 1869 U.N.T.S. 299, 33 I.L.M. 1197, art. 65 (1994), http://www.wto.org/english/docs_e/legal_e/27-trips.pdf
―, document WT/TPR/M/75 (6 December 2000).
―, ‘Responding to Least Developed Countries’ Special Needs in Intellectual Property’ (updated in 2012), http://www.wto.org/english/tratop_e/trips_e/ldc_e.htm
―, ‘Panel Report, Canada—Term of Patent Protection’ (WT/DS170/R, 5 May 2000).
―, ‘Panel Report, Canada—Patent, Complaint by US, at 6.56; Appellate Report, Canada—Term of Patent Protection’ (WT/DS170/AB/R, 11 August 2000).
―, ‘Implementation of paragraph 6 of the Doha Declaration on the TRIPS agreement and public health. Decision of 30 August 2003’ (WT/L/540, 2 September 2003).
―, ‘WTO and the Least Developed Countries’ http://www.wto.org/english/thewto_e/whatis_e/tif_e/org7_e.htm
―, ‘Decision of the Council for TRIPS on the Extension of the Transition Period under Article 66.1 of the TRIPS Agreement for Least-developed Country Members for Certain Obligations with Respect to Pharmaceutical Products’ (27 June 2002, Document IP/C/25).
―, ‘Brazil: Measures Affecting Patent Protection’ (Dispute Settlement: Dispute DS199, WTO), http://www.wto.org/english/tratop_e/dispu_e/cases_e/ds199_e.htm
―, ‘Decision of The Council for TRIPS of 11 June 2013’ (Document IP/C/64).
―, ‘Communication from Bangladesh on behalf of the LDC Group’ (23 February 2015, document IP/C/W/605).
―, ‘Decision of the Council for TRIPS’ (6 November 2015, document IP/C/73).
―, ‘Notification of Rwanda’ (July 2007, document IP/N/9/RWA/1).
―, ‘Notification of Canada’ (October 2007, document IP/N/10/CAN/1).
―, ‘Communication from Haiti on Behalf of the LDC Group: Request for an Extension of the Transitional Period under Article 66.1 of the TRIPS Agreement’ (5 November 2012, IP/C/W/583).
―, ‘Developing Countries’ Transition Periods’, Fact Sheet: TRIPS and Pharmaceutical Patents, http://www.wto.org/english/tratop_e/trips_e/factsheet_pharm04_e.htm
―, Intellectual Property: Least Developed Countries, https://www.wto.org/english/tratop_e/trips_e/ldc_e.htm
WTO Council for TRIPS, ‘Relationship Between the TRIPS Agreement and the CBD, and the Protection of Traditional Knowledge’ (18 June 2003, IP/C/W/400/Rev.1), http://docsonline.wto.org/imrd/directdoc.asp?DDFDocuments/t/IP/C/W400R1.doc
―, ‘Priority Needs for Technical and Financial Co-operation: Communication from Bangladesh’ (23 March 2010, IP/C/W/546).
―, ‘Elements of the Obligation to Disclose the Source and Country of Origin of Biological Resource and/or Traditional Knowledge Used in an Invention’ 2 (21 September 2004 (IP/C/W/429), http://docsonline.wto.org/imrd/directdoc.asp?DDFDocuments/t/IP/C/W429.doc
Yunus, Muhammad, Creating a World without Poverty: Social Business and the Future of Capitalism (Philadelphia: Public Affairs, 2008).
―, and Qamrul Alam, ‘WTO TRIPS Agreement—Current State of Pharmaceutical Industry and Policy Options for Bangladesh’, International Business Research, 1.1 (2008), http://dx.doi.org/10.5539/ibr.v1n1p135
―, Building Social Business: The New Kind of Capitalism That Serves Humanity’s Most Pressing Needs (Philadelphia, PA: Public Affairs, 2010).
Zainal, Zaidah, Case Study As a Research Method, http://psyking.net/htmlobj-3837/case_study_as_a_research_method.pdf
Zhang, Haiyang, ‘Rethinking the Patent System from the Perspective of Economies’, in Emerging Markets and the World Patent Order, ed. by Federick M. Abbott, Carlos M. Correa and Peter Drahos (Cheltenham: Edward Elgar, 2013), pp. 61–77, http://dx.doi.org/10.4337/9781783471256.00011